Herta M Crauwels
Overview
Explore the profile of Herta M Crauwels including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
177
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ackaert O, McDougall D, Perez-Ruixo C, Perez-Ruixo J, Jezorwski J, Crauwels H
AAPS J
. 2021 Jun;
23(4):82.
PMID: 34100149
The single-tablet regimen darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg has undergone phase III studies AMBER (NCT02431247) and EMERALD (NCT02269917) in HIV-infected patients. An existing population pharmacokinetic (PopPK) model for cobicistat-boosted darunavir...
2.
MacBrayne C, Rutstein R, Wiznia A, Graham B, Alvero C, Fairlie L, et al.
AIDS
. 2021 Apr;
35(9):1413-1421.
PMID: 33831904
Objective: To describe the pharmacokinetics, safety, and efficacy of etravirine (ETR) in HIV-infected children 1 to less than 6 years of age. Design: Phase I/II, open-label, multicenter, dose-finding study. Methods:...
3.
Crauwels H, Baugh B, Van Landuyt E, Vanveggel S, Hijzen A, Opsomer M
Clin Pharmacol Drug Dev
. 2018 Nov;
8(4):480-491.
PMID: 30412360
The effect of food on the bioavailability of the components of the once-daily, single-tablet human immunodeficiency virus (HIV) type 1 regimen containing darunavir (DRV 800 mg), cobicistat (COBI 150 mg),...
4.
Osiyemi O, Yasin S, Zorrilla C, Bicer C, Hillewaert V, Brown K, et al.
Infect Dis Ther
. 2018 Jan;
7(1):147-159.
PMID: 29335895
Introduction: Physiologic changes during pregnancy may impact the pharmacokinetics of drugs. In addition, efficacy and safety/tolerability concerns have been identified for some antiretroviral agents. Methods: Human immunodeficiency virus (HIV)-1-infected pregnant...
5.
Ramgopal M, Osiyemi O, Zorrilla C, Crauwels H, Ryan R, Brown K, et al.
J Acquir Immune Defic Syndr
. 2016 May;
73(3):268-274.
PMID: 27159225
Background: Treatment of HIV-1-infected women during pregnancy protects maternal health and reduces the risk of perinatal transmission of HIV-1. However, physiologic changes that occur during pregnancy may affect drug pharmacokinetics....
6.
Williams P, Crauwels H, Basstanie E
Curr Opin HIV AIDS
. 2015 Jun;
10(4):233-8.
PMID: 26049947
Purpose Of Review: Rilpivirine (RPV), a nonnucleoside reverse transcriptase inhibitor, is a potent antiretroviral (ARV) effective for HIV treatment at 25 mg daily oral dose. Its physio-chemical and pharmacological properties...
7.
Kakuda T, Leopold L, Nijs S, Vandevoorde A, Crauwels H, Bertelsen K, et al.
J Clin Pharmacol
. 2015 May;
54(5):563-73.
PMID: 25975423
Coinfection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) may require treatment with an HIV non-nucleoside reverse transcriptase inhibitor (NNRTI), for example, rilpivirine or etravirine, and an HCV...
8.
Crauwels H, van Heeswijk R, Vandevoorde A, Buelens A, Stevens M, Hoetelmans R
J Clin Pharmacol
. 2013 Nov;
54(2):133-40.
PMID: 24203510
Antiretrovirals may influence methadone exposure in HIV-1-infected patients receiving methadone for opiate addiction. Rilpivirine is a non-nucleoside reverse transcriptase inhibitor for treating HIV-1 infection. In this open-label trial (NCT00744770), 13...
9.
Crauwels H, van Heeswijk R, Buelens A, Stevens M, Hoetelmans R
Int J Clin Pharmacol Ther
. 2013 Oct;
52(2):118-28.
PMID: 24161160
Unlabelled: Rilpivirine is a human immunodeficiency virus Type 1 (HIV-1) non-nucleoside reverse transcriptase inhibitor. Objective: Rilpivirine metabolism involves cytochrome P450 3A4 (CYP3A4). This trial (ClinicalTrials. gov number: NCT00739622) evaluated the...
10.
Crauwels H, van Heeswijk R, Buelens A, Stevens M, Boven K, Hoetelmans R
J Clin Pharmacol
. 2013 May;
53(8):834-40.
PMID: 23720136
The objective of the study was to determine the impact of food and different meal types on the pharmacokinetics of rilpivirine, a nonnucleoside reverse transcriptase inhibitor. In this open-label, randomized,...